基于连接组与基于头皮定位的加速经颅磁刺激治疗抑郁症:一项随机临床试验
这项随机临床试验纳入40例中重度难治性抑郁症成人,比较基于功能连接组与基于头皮Beam F3方法定位的加速经颅磁刺激(aTMS)疗效。
要点
- 连接组定位效应量Cohen d为0.8(95%CI 0.26-1.54),需扫描人数为5。
核心结论
- 基于个体化连接组靶向收敛抑郁症环路的aTMS增强了高剂量aTMS的抗抑郁效果。
- 结果可用于成本效果分析并为确证性疗效试验提供样本量估算依据。
研究设计与样本
- 随机临床试验,2023年7月至2025年3月在麻省总医院脑环路治疗中心开展。
- 纳入40例22至80岁原发性重性抑郁障碍成人,MADRS评分为中重度且Maudsley分期为中重度治疗抵抗。
- 参与者、TMS技师和研究医师均设盲,主要结局为治疗后1个月MADRS评分(基线校正)。
主要发现
- 连接组定位效应量Cohen d为0.8(95%CI 0.26-1.54),需扫描人数为5。
关键数值与推荐
- 连接组靶点定义为左侧背外侧前额叶皮层中与已发表收敛抑郁症环路相关性最高的区域。
- 收敛抑郁症环路包括与膝下扣带回皮层的负连接等多个抑郁相关脑区。
- 头皮靶点采用Beam F3方法识别。
临床怎么用
- 对于中重度难治性抑郁症患者,可考虑基于功能连接组神经影像个体化定位aTMS靶点以增强抗抑郁效果。
- 连接组定位需在aTMS前完成41分钟多回波静息态功能连接扫描。
局限性
- 样本量较小(40例),研究结果需确证性试验验证。
- 研究在单一中心开展,外部推广性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neuroimaging is prevalent in psychiatric research, but there is limited evidence that it improves clinical outcomes. Functional connectivity neuroimaging was recently used to target individualized brain circuits with accelerated transcranial magnetic stimulation (aTMS), with rapid antidepressant effects and US Food and Drug Administration clearance, but the importance of connectivity-based targeting remains unclear. OBJECTIVE: To estimate the effect size of connectivity- vs scalp-based targeting of aTMS for treatment-resistant depression. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial comparing connectivity- to scalp-based aTMS treatment was conducted between July 2023 and March 2025 with the primary outcome assessed at 1 month posttreatment and follow-up every 3 months for 1 year. Participants, TMS technicians, and study physicians were blinded. The study took place at the Center for Brain Circuit Therapeutics at Mass General Brigham and Harvard Medical School in Boston, Massachusetts. Forty adults aged 22 to 80 years with a primary diagnosis of major depressive disorder with moderate to severe depression per Montgomery-Åsberg Depression Rating Scale (MADRS) score and moderate to severe treatment resistance per Maudsley Staging Method were included. Key exclusion criteria included contraindications to TMS or magnetic resonance imaging, primary psychiatric diagnoses other than major depressive disorder or anxiety disorders, recent rapid-acting antidepressant treatments, and significant neurological or substance use disorders. INTERVENTIONS: All participants underwent a 41-minute multiecho resting-state functional connectivity scan prior to aTMS, and half of them received treatment guided by these data. The connectivity-based target was defined as the left dorsolateral prefrontal cortex region with the greatest correlation to a published and publicly available convergent depression circuit. This circuit includes multiple brain regions linked to depression, including negative connectivity to the subgenual cingulate cortex. The scalp-based target was identified with the Beam F3 method. MAIN OUTCOMES AND MEASURES: MADRS score 1 month after treatment, adjusted for baseline. RESULTS: In total, 40 participants (22 female [55%]; mean [SD] age, 45.7 [15.2] years) were randomized and treated. The median (IQR) MADRS score reduction was 24 (19-28) vs 18 (10-23) points with connectivity- vs scalp-based targeting, respectively (P = .02). Connectivity-based targeting had an effect size of 0.8 (Cohen d analog) and 95% CI of 0.26-1.54, with a number needed to scan of 5 individuals. Individualized targets were reproducible within an individual (4.47 mm split-half distance) and different between individuals (12.97 mm) (P < .001). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, individualized, connectivity-based targeting of the convergent depression circuit enhanced the antidepressant effects of high-dose aTMS. These results could facilitate cost-effectiveness analyses and help to power a confirmatory efficacy trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05680727.
引用
- Taylor JJ, Kare MR, Haj-Darwish D, et al. Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 42340706. doi:10.1001/jamapsychiatry.2026.1100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。